Amgen (AMGN -0.7%) underperformed a little today after a U.S. appeals court gave a green light to a securities class-action lawsuit accusing the company of failing to disclose safety information for two anemia drugs, and of promoting unauthorized uses of its products.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs